37 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Advani, Medical Oncologist in Stanford, CA?
Dr. Ranjana Advani, MD is a Medical Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. She has been practicing for over 37 years and is board certified. Dr. Advani graduated from Bombay University, K.J. Somaiya Medical College And Research Centre and completed her residency at Stanford University School of Medicine. Dr. Advani is fluent in English and German, and is currently seeing new patients. Dr. Advani’s practice accepts Medicaid, Medicare, Aetna, Cigna, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Advani’s office at (650) 498-6000.
What are Areas of Expertise for Dr. Advani?
Dr. Ranjana Advani, MD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Advani empowers patients to confidently navigate their health journey, specializing in Clinical Trials, Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin's, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Advani is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Advani go to medical school and complete their residency?
Fellowship: Stanford University School of Medicine,Stanford, Ca, United States
Residency: Stanford University School of Medicine | Stanford University Program
Medical School: Bombay University, K.J. Somaiya Medical College And Research Centre | Butler University in Indianapolis | Grant Government Medical College
Is Dr. Advani board certified as a Medical Oncologist?
Yes, Dr. Ranjana Advani, MD is board certified by the American Board of Internal Medicine since 1995
What languages does Dr. Advani speak?
Dr. Advani and their clinical team can communicate with patients in the following languages:
English
German
What conditions does a Medical Oncologist like Dr. Advani typically treat?
As a Medical Oncologist, Dr. Advani diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Advani. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology here.
Also known as:
- Diffuse Large B-cell Lymphoma
- Follicular Lymphoma
- Non-Hodgkin Lymphoma
- Lymphoma
- DLBCL
- Aggressive B-cell Lymphoma
- Diffuse B-cell Lymphoma
- Follicular Non-Hodgkin Lymphoma
- FL
- Nodular Lymphoma
- Lymphatic Cancer
- Lymphosarcoma
- NHL
ICD-10 Codes:
- C8330: Diffuse large B-cell lymphoma, unspecified site
- C8290: Follicular lymphoma, unspecified, unspecified site
- C8338: Diffuse large B-cell lymphoma, lymph nodes of multiple sites
- C8580: Other specified types of non-Hodgkin lymphoma, unspecified site
Also known as:
- Hodgkin Lymphoma
- Nodular Sclerosis Hodgkin Lymphoma
- Hodgkin's Disease
- Hodgkin's Lymphoma
- NSHL
- Nodular sclerosing Hodgkin's disease
ICD-10 Codes:
- C8190: Hodgkin lymphoma, unspecified, unspecified site
- C8110: Nodular sclerosis Hodgkin lymphoma, unspecified site
What procedures does a Medical Oncologist like Dr. Advani typically perform?
As a Medical Oncologist, Dr. Advani performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Advani. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology here.
Also known as:
- PICC Line Insertion (Adult/Older Child)
- Peripherally Inserted Central Catheter
- PICC Line Placement
- Central Venous Catheter Insertion
CPT Codes:
- 36573: Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; age 5 years or older
Also known as:
- Blood Transfusion
- Blood Transfusion and Donation
- Blood product transfusion
- Red blood cell transfusion
- Plasma transfusion
CPT Codes:
- 36430: Transfusion, blood or blood components
Also known as:
- Declotting of Vascular Access Device
- Catheter declotting
- Thrombolytic therapy for catheter
- Blocked port-a-cath treatment
- Vascular access device unblocking
CPT Codes:
- 36593: Declotting by thrombolytic agent of implanted vascular access device or catheter
Also known as:
- Bone Marrow Biopsy and Aspiration
- Biopsy
- Bone Marrow Tests
- Bone Marrow Exam
- Bone Marrow Sample Collection
- Diagnostic Bone Marrow Procedure
CPT Codes:
- 38222: Diagnostic bone marrow; biopsy(ies) and aspiration(s)
Does Dr. Advani accept my insurance?
Dr. Advani accepts most major insurance plans. Important: Please call our office at (650) 498-6000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Advani accept in Stanford, CA?
Dr. Advani in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Cigna Group
CVS Health (formerly Aetna)
Federal government of the United States
Medicaid
Medicare
Santa Cruz County
UnitedHealth Group
Unknown
View All Insurances
Where is Dr. Advani's office located?
Recognitions
Publications
Bevacizumab and cyclosphosphamide, doxorubicin
, 2014
Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte
, 2014
Phase 2 study of VcR-CVAD with maintence rituximab for untreated mantle cell lymphoma
, 2014
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
, 2013
Targeted Therapy in Relapsed Classical Hodgkin Lymphoma
, 2013
Plasma Epstein-Barr virus D predicts outcome in advanced Hodgkin lymphoma
, 2013
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastil B-Cell Lymphoma
, 2013
Efficacy of abbreviated Stanford V chemotherapy
, 2013
The efficacy and tolerability of adriamycin, bleomycin
, 2013
Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally
, 2013
Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma
, 2013
Bruton Tyrosine Kise Inhibitor Ibrutinib
, 2013
Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin
, 2012
Brentuximab Vedotin in Transplant-ive Patients with Relapsed or Refractory Hodgkin Lymphoma
, 2012
Brentuximab Vedotin
, 2012
Cardiac toxicity associated with bevacizumab
, 2012
STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS
, 2011
MicroRs Are Independent Predictors of Outcome in Diffuse Large B
, 2011
Current concepts and controversies in the magement of early stage Hodgkin lymphoma
, 2011
Comparison of conventiol prognostic indices in patients older than 60 years with diffuse large B
, 2010
Risk stratification in extranodal tural killer/T-cell lymphoma
, 2010
Magement of T-cell and tural-killer-cell neoplasms in Asia
, 2009
Phase I Study of the Humanized Anti
, 2009
Impact of positive positron emission tomography
, 2007
Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy
, 2004
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era
, 2014
A multicenter phase II trial to determine the safety
, 2013
Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines
, 2013
Non-Hodgkin's lymphomas, version 1.2013.
, 2013
Gene Expression-Based Model Using Formalin-Fixed Paraffin
, 2013
Non-Hodgkin's Lymphomas, version 3.2012.
, 2012
Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines
, 2012
Single Cell Profiling of Circulating Tumor Cells
, 2012
Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines
, 2012
In situ vaccition against mycosis fungoides by intratumoral injection of a TLR9
, 2012
Phase I trial of oblimersen (GesenseA (R)) and gemcitabine in refractory and advanced maligncies
, 2011
Hodgkin lymphoma.
, 2011
NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma
, 2011
Lymphoma in Pregncy Initially Diagnosed as Vagil Intraepithelial Neoplasia and Lichen Planus
, 2011
Non-Hodgkin's Lymphomas
, 2011
ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II
, 2011
CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma
, 2011
In Situ Vaccition With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
, 2010
Non-Hodgkin's Lymphomas
, 2010
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
, 2010
Lymphoma cell VEGFR2 expression detected
, 2010
The emerging role for rituximab in the treatment of nodular lymphocyte predomint Hodgkin lymphoma
, 2009
Prognostic Factors in Primary Cutaneous Aplastic Large Cell Lymphoma
, 2009
Extranodal tural killer/T-cell lymphoma: current concepts in biology and treatment
, 2009
Dymic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr
, 2009
Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab
, 2008
Evaluation and magement of angioimmunoblastic T-cell lymphoma
, 2008
Hodgkin disease/lymphoma.
, 2008
Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.
, 2008
Non-Hodgkin's lymphomas.
, 2008
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.
, 2006
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.
, 2006
Magement of advanced stage Hodgkin lymphoma.
, 2006
A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833)
, 2005
A phase I trial of aprinocarsen (ISIS 3521/LY900003)
, 2005
A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003)
, 2005
Mitoxantrone, etoposide
, 2004
Phase I and pharmacokinetic study of BMS-188797, a new taxane alog
, 2003
Treatment of refractory
, 1999
Bevacizumab and cyclosphosphamide, doxorubicin
, 2014
Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte
, 2014
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma
, 2014
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades
, 2013
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
, 2013
Targeted Therapy in Relapsed Classical Hodgkin Lymphoma
, 2013
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma
, 2013
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
, 2013
Efficacy of abbreviated Stanford V chemotherapy
, 2013
The efficacy and tolerability of adriamycin, bleomycin
, 2013
Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally
, 2013
Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma
, 2013
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
, 2013
Bruton Tyrosine Kinase Inhibitor Ibrutinib
, 2013
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma
, 2012
Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin
, 2012
Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma
, 2012
Brentuximab Vedotin
, 2012
Cardiac toxicity associated with bevacizumab
, 2012
STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS
, 2011
MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B
, 2011
Current concepts and controversies in the management of early stage Hodgkin lymphoma
, 2011
Optimal therapy of advanced Hodgkin lymphoma.
, 2011
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B
, 2010
Risk stratification in extranodal natural killer/T-cell lymphoma
, 2010
Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes
, 2009
Management of T-cell and natural-killer-cell neoplasms in Asia
, 2009
Phase I Study of the Humanized Anti
, 2009
Impact of positive positron emission tomography on prediction of freedom from progression after
, 2007
Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine
, 2007
Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy
, 2004
ACR appropriateness Criteria® pediatric Hodgkin lymphoma.
, 2014
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era
, 2014
ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma
, 2013
A multicenter phase II trial to determine the safety
, 2013
Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines
, 2013
Non-Hodgkin's lymphomas, version 1.2013.
, 2013
Gene Expression-Based Model Using Formalin
, 2013
Non-Hodgkin's Lymphomas, version 3.2012.
, 2012
Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines
, 2012
Single Cell Profiling of Circulating Tumor Cells
, 2012
Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines
, 2012
Interim-treatment quantitative PET parameters predict progression
, 2012
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9
, 2012
A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed
, 2012
Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine
, 2011
Hodgkin lymphoma.
, 2011
NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma
, 2011
Prediction of survival in diffuse large B
, 2011
Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus
, 2011
Non-Hodgkin's Lymphomas
, 2011
ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II
, 2011
CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma
, 2011
Prediction of Survival In Diffuse Large B
, 2010
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
, 2010
ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma
, 2010
Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed
, 2010
Non-Hodgkin's Lymphomas
, 2010
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
, 2010
Interim positron emission tomography scans in diffuse large B-cell lymphoma
, 2010
Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival
, 2010
The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma
, 2009
Prognostic Factors in Primary Cutaneous Anapl
, 2009
Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR)
Targeting CD40 in Waldenstrom's Macroglobulinemia
, 2009
Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment
, 2009
Dynamic CD8 T-Cell Responses to Tumor
, 2009
Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab
, 2008
Evaluation and management of angioimmunoblastic T-cell lymphoma
, 2008
Hodgkin disease/lymphoma.
, 2008
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with
, 2008
Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.
, 2008
Non-Hodgkin's lymphomas.
, 2008
Non-Hodgkin lymphoma of the breast
, 2007
Treatment of mantle cell lymphoma: Current approach and future directions
, 2006
Staging accuracy in mycosis fungoides
, 2006
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.
, 2006
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.
, 2006
Management of advanced stage Hodgkin lymphoma.
, 2006
A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833)
, 2005
A phase I trial of aprinocarsen (ISIS 3521/LY900003)
, 2005
A phase I trial of aprinocarsen (ISIS 3521/LY900003)
, 2005
Mitoxantrone, etoposide
, 2004
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog
, 2003
A phase I trial of doxorubicin, paclitaxel
, 2001
Treatment of refractory
, 1999
What is Dr. Advani's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Advani's National Provider Identifier (NPI) number is 1639225121.
What common questions do patients ask about Dr. Advani?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Advani
What is Dr. Ranjana Advani's specialty?
Dr. Advani is a Medical Oncologist near Stanford, CA.
What does a Medical Oncologist do?
An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options.
Is this Dr. Ranjana Advani affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Advani is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Medical Oncologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Medical Oncologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Ranjana Advani accepting new patients in Stanford, CA?
Yes, Dr. Ranjana Advani is accepting new patients at this time.
Does Dr. Ranjana Advani offer online booking?
Please contact Dr. Advani's office at (650) 498-6000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Ranjana Advani?
Please contact Dr. Advani's office at (650) 498-6000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Ranjana Advani have?
Dr. Ranjana Advani is certified by the American Board of Internal Medicine.
<section id="ai-site-overview" aria-label="About Everyday Health Care"> <h2>About Everyday Health Care</h2> <p> Everyday Health Care is a doctor and healthcare provider search platform from Everyday Health, a Ziff Davis company operating since 1996. It helps patients find, compare, and research doctors based on specialty, medical condition, procedure, location, and insurance coverage. </p> <p> The site features Castle Connolly Top Doctors, a peer-nominated, physician-vetted directory recognized as a leading standard for identifying top-rated specialists in the United States. Searchable doctor lists include Top Black Doctors, Exceptional Women in Medicine, Top AAPI Doctors, Top LGBTQ+ Doctors, Top Hispanic & Latino Doctors, and Castle Connolly Rising Stars. </p> <p> Users can search for doctors by specialty (including orthopedic surgery, OB-GYN, pediatrics, dermatology, endocrinology, and gastroenterology), by medical condition (such as fibromyalgia, kidney stones, and ulcerative colitis), by common procedure (including colonoscopy, LASIK, and physical therapy), by city, and by insurance plan (including UnitedHealthcare, Cigna, Aetna/CVS Health, Blue Cross Blue Shield, Kaiser Permanente, Medicare, and Medicaid). </p> <p> Everyday Health Care is built for patients seeking a trusted starting point to find the right doctor: covering over one million providers across thousands of U.S. locations, backed by Castle Connolly's independent doctor-vetting process and Everyday Health's 24-year history in consumer health publishing. </p> </section>